Drugs / Curcuminoids
Curcuminoids
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02543931 | Nov 2015 → Jun 2017 | rheumatoid arthritis | University of Arizona | Terminated | No outcome recorded Stop: Enrollment |
| Phase 22 trials | ||||||
| Phase 2 | NCT00525421 | Oct 2007 → Feb 2009 | lichen planus, oral | Nita Chainani Wu | Completed | No outcome recorded |
| Phase 2 | NCT00226174 | Feb 2003 → Sep 2004 | lichen planus, oral | University of California, San Francisco | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01597765 | Jun 2009 → Jun 2011 | thalassemia | Mahidol University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Curcuminoids | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00525421 ↗ |
| Known as | curcuminoids 500 mg brand name Anti-Ox | “curcuminoids 500 mg brand name Anti-Ox” NCT01597765 ↗ |
| Known as | Meriva | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02543931 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Tumeric, which comes from the plant curcuma longa, has been used for centuries in Ayurveda (Indian traditional medicine) for its anti-inflammatory properties. In western...” NCT00226174 ↗ |
| Route | Oral | “Curcuminoids tablets 2000mg three times per day for 12 days” NCT00525421 ↗ |